industry

Lupin's Vizag unit gets no observations from USFDA


Drug maker Lupin on Friday said a pre-approval and good manufacturing practices (GMP) inspection conducted by USFDA of its active pharmaceutical ingredient (API) manufacturing facility in Visakhapatnam concluded without any observations.

The inspection was conducted from March 6 – 10, 2023

“We are pleased with the successful completion of the inspection at our Vizag facility,” said Nilesh Gupta, managing director of Lupin.

“This accomplishment is a testament to our commitment to upholding global quality standards across all our manufacturing sites, and to provide quality affordable healthcare for all,” Gupta added.



READ SOURCE

Readers Also Like:  As demand for refurbished IT hardware surges, laptop companies click on reboot plan to sell used devices

This website uses cookies. By continuing to use this site, you accept our use of cookies.